RAPP
What one share of Rapport Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders. Our foundational science has elucidated the complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes.
Rapport Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.05 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.16 |
| Cash and investments | $1.33 |
| Book value | $8.82 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$23.10 | $1.09 | −$19.14 | — | — |
| 2024 | — | −$3.78 | $0.12 | −$3.24 | — | $8.35 |
| 2025 | — | −$2.86 | $0.02 | −$2.26 | — | $10.14 |